Cancer Biomarkers Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Cancer Biomarkers Market Analysis

The Cancer Biomarkers Market size is estimated at USD 21.37 billion in 2025, and is expected to reach USD 32.54 billion by 2030, at a CAGR of 8.77% during the forecast period (2025-2030).

The cancer biomarkers market is poised for significant growth driven by technological advancements, a paradigm shift in healthcare from disease diagnosis to risk assessment or early diagnosis, increasing cancer incidence, and the trend toward personalized medicine. The rising number of cancer cases globally necessitates developing and using effective diagnostic and therapeutic solutions, propelling the demand for biomarkers. For instance, according to the data published by the International Agency for Research on Cancer in February 2024, the estimated number of new cancer cases in 2022 was reported to be 20 million globally which is expected to reach 32.6 million by 2045. The rising global cancer burden is expected to drive the demand for diagnostic cancer biomarkers, fuelling market growth during the forecast period.

Moreover, the development of liquid biopsy tests that use blood samples to detect cancer biomarkers non-invasively is gaining traction as a less invasive alternative to traditional tissue biopsies. For instance, in August 2023, the American Association for Cancer Research published data highlighting the promising results of ongoing research and numerous clinical trials using liquid biopsies for cancer detection. This underscores the growing potential of liquid biopsies in detecting and monitoring cancer, which is expected to propel the market growth over the forecast period.

Furthermore, the rise of immunotherapy drives demand for biomarkers that can predict responses to these therapies, opening new avenues for industry research and product development. However, developing and validating new biomarkers can be expensive and time-consuming, posing a challenge for smaller companies. In addition, inconsistent insurance coverage and reimbursement policies for biomarker testing can hinder widespread adoption of cancer biomarkers, which is likely to impede the market growth over the forecast period.

Cancer Biomarkers Market Insights and Trends

Genetic Biomarkers Segment is Expected to Have Significant Growth as per this Market Forecast

By type, the genetic biomarkers segment is estimated to have a market size of USD 7.42 billion in 2024 which is expected to reach USD 12.31 billion by 2029 with a CAGR of 8.72% over the forecast period.

A genetic biomarker is a DNA sequence that causes disease or is associated with disease susceptibility. Some examples of genetic biomarkers are gene expression changes, single-nucleotide polymorphisms (SNPs), patterns of open or closed chromatin, or polygenic risk scores (PRS). Several studies identified genetic biomarkers for therapy in various solid tumors, including gene mutations, DNA methylation, long non-coding RNAs (lncRNAs), microRNAs (miRNAs), and circular RNA (circRNA). The factors driving the genetic biomarkers segment growth include the increase in the identification of these biomarkers for various genetic disorders and advancement in research and development for genetic biomarker therapies, among others.

The rise in the use of bioinformatics to identify genetic biomarkers has further propelled market growth, and it is expected to do the same over the forecast period. For instance, according to the study published in Scientific Reports in November 2023, integrated bioinformatics approaches such as the gene ontology (GO) and KEGG pathway enrichment analysis, molecular dynamic simulation, molecular docking, and network-based molecular interaction analysis are increasingly used as a tool for the identification of genetic biomarkers. Therefore, the adoption of bioinformatics in identifying genetic markers helps identify many genetic biomarkers, thereby increasing the demand for the segment studied.

Furthermore, the rising advantages of genetic biomarkers for solid tumor detection and treatment are also anticipated to contribute significantly to segment growth. For instance, according to the study published in Frontiers in Genetics in May 2023, the metabolism-related genetic biomarker has the potential to diagnose solid tumors by identifying the target. This will also help researchers to design therapies according to the genetic biomarkers, thereby developing innovative therapies. Therefore, owing to the increased research and development on the identification of genetic biomarkers and varied advantages are all the factors contributing to the segment growth.

Breast Cancer Segment is Expected to Have Fastest Growth in the Market Over the Forecast Period

In 2024, the breast cancer segment is projected to dominate the cancer biomarkers market share, boasting a market size of USD 3.01 billion. This segment is anticipated to grow to USD 4.58 billion by 2029, achieving a CAGR of 8.69% during the forecast period.

The breast cancer segment is a significant and rapidly expanding area within the cancer biomarkers market. The segment is poised for substantial growth due to a confluence of rising breast cancer incidence rates, technological advancements in screening breast cancer, and a focus on personalized medicine. With the continuous discovery and validation of new biomarkers, this segment is poised for ongoing expansion and innovation. However, the heterogeneity of breast cancer can lead to variability in biomarker expression between cancer patients. This variability can make it difficult to generalize the utility of specific biomarkers across diverse populations.

The cancer biomarkers market segmentation includes disease, type, and profiling technology. By disease, the market is segmented into prostate cancer, breast cancer, lung cancer, colorectal cancer, cervical cancer, and other diseases. By type, the market is segmented into protein biomarkers, genetic biomarkers, and other types. By profiling technology, the market is segmented into OMICS technology, imaging technology, immunoassays, and others. Each of these segments is experiencing growth due to factors like advancements in screening cancer biomarkers and increasing demand for early diagnosis of various cancers.

Europe is Expected to Have Significant Share in the Market Over the Forecast Period

By geography, the European region is likely to hold a major cancer biomarkers market share with an estimated market size of USD 4.21 billion in 2024, expected to reach USD 6.33 billion by 2029 with a CAGR of 8.48% over the forecast period. The European region is poised for a significant growth rate due to a combination of rising cancer incidence, technological advancements in screening cancer biomarkers, and shifts toward personalized healthcare.

The increase in cancer cases across Europe is expected to necessitate advanced cancer biomarkers testing, which is likely to drive the market growth over the forecast period. For instance, according to the 2023 update of the European Cancer Information System (ECIS), about 2.85 million new cases of cancer are likely to be reported by 2025 in the European Union-27 (EU-27) countries, and it is expected to reach 3.13 million by 2035. The burden of cancer in EU-27 is anticipated to increase over the years owing to the aging population and improvement in cancer diagnosis infrastructure in the region.

Active cancer biomarker companyies and their strategies, such as collaborations and partnerships for expanding the business of cancer biomarker solutions in the countries and product launches, increase the availability of cancer biomarker diagnostic tests for end users, which is anticipated to boost market growth. For instance, in February 2024, Mainz Biomed NV announced the distribution partnership with Praxisdienst to improve the accessibility of the ColoAlert screening test across Germany, which is incorporated with novel mRNA biomarkers that lead to high sensitivity and specificity for the detection of colorectal cancer by the identification of tumor DNA in stool samples. Therefore, the European market for cancer biomarkers is anticipated to grow over the forecast period due to the aforementioned factors, such as the growing geriatric population, increasing number of cancer cases, and increasing company activities.

By geography, the global market is segmented into North America (United States, Canada, Mexico), Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, Rest of Middle East and Africa), and South America (Brazil, Argentina, Rest of South America). Countries like China and India increasingly adopt biomarker testing and diagnostics as part of their healthcare strategies. The Middle East and Africa market is still developing, with limited access to advanced diagnostic technologies.